Varying mRNA and protein expression levels of COL11A1 at different stages and sites of the tumor suggests COL11A1 as a potential biomarker, with the highest COL11A1 levels detected in late stage disease (recurrent metastases) and lowest levels in earlier stage disease (primary ovarian tumors) (19). This evidence concerns the gene COL11A1 and neoplasm.